Immunai Technologies, founded in 2018 and headquartered in the United States, has raised about $295 million in funding, including a $215 million Series B round in October 2021 led by Koch Disruptive Technologies, valuing it near $1 billion. The company develops the AMICA platform - an annotated multi‑omic immune cell atlas combined with AI and functional genomics - to decode the immune system and speed discovery of immunomodulatory therapeutics. With investors like Catalio Capital and Alexandria Venture Investments, Immunai is positioned at the forefront of precision immunology and therapeutic innovation.